Literature DB >> 23033232

Drug-drug interactions between warfarin and psychotropics: updated review of the literature.

Ashwini Nadkarni1, Mark A Oldham, Mark Howard, Isidore Berenbaum.   

Abstract

As the number of psychotropics on the market expands, the likelihood increases that a patient requiring anticoagulation with warfarin will receive concurrent treatment with a psychotropic drug. Because warfarin undergoes hepatic metabolism and is highly protein bound, it is particularly prone to drug interactions; in addition, its relatively narrow therapeutic window places patients at risk of either hemorrhagic or thrombotic complications. Although warfarin's interactions with other drugs have long been studied, the most recent review of the literature of warfarin's interactions with psychotropics was over a decade ago. Thus, we conducted a systematic review of the literature documenting the interaction between warfarin and psychotropics, with a focus on interactions mediated through the cytochrome P450 system and protein binding. A search of the MEDLINE database was performed, and reports of warfarin interactions with psychotropics were identified. The results suggest that interactions between warfarin and psychotropic drugs are important and likely underrecognized. They also have notable implications for both safety and drug compliance. When certain psychotropics are started or discontinued in patients receiving warfarin therapy, or when warfarin is introduced to a patient receiving a stable dose of a psychotropic, clinicians should monitor a patient's international normalized ratio (INR) closely to ensure it remains within therapeutic range. Psychotropics that pose a particular risk of increasing the INR when used with warfarin include fluoxetine, fluvoxamine, quetiapine, and valproic acid. Psychotropics that may significantly decrease the INR when used with warfarin include trazodone, St. John's wort, carbamazepine, and the polycyclic aromatic carbons in tobacco cigarettes; however, nicotine itself, as in nicotine replacement strategies, is not known to alter warfarin's anticoagulant effect. In certain cases, the need for anticoagulation may also necessitate switching to a different psychotropic.
© 2012 Pharmacotherapy Publications, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23033232     DOI: 10.1002/j.1875-9114.2012.01119

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  7 in total

1.  Independent predictors of delay in emergence from general anesthesia.

Authors:  Shigeru Maeda; Yumiko Tomoyasu; Hitoshi Higuchi; Minako Ishii-Maruhama; Masahiko Egusa; Takuya Miyawaki
Journal:  Anesth Prog       Date:  2015

2.  Deliberate self-poisoning with long-acting anticoagulant rodenticides.

Authors:  Danielle Reimer; Melissa Smith; Sayed Ali
Journal:  BMJ Case Rep       Date:  2017-12-20

Review 3.  Drug Interactions Affecting Oral Anticoagulant Use.

Authors:  Philip L Mar; Rakesh Gopinathannair; Brooke E Gengler; Mina K Chung; Arturo Perez; Jonathan Dukes; Michael D Ezekowitz; Dhanunjaya Lakkireddy; Gregory Y H Lip; Mike Miletello; Peter A Noseworthy; James Reiffel; James E Tisdale; Brian Olshansky
Journal:  Circ Arrhythm Electrophysiol       Date:  2022-05-27

4.  Warfarin-quetiapine interaction causing hemorrhage.

Authors:  Amar D Bavle; Sharath Vishwaraj
Journal:  Indian J Psychiatry       Date:  2016 Jan-Mar       Impact factor: 1.759

Review 5.  A systematic review of St. John's wort for major depressive disorder.

Authors:  Eric A Apaydin; Alicia R Maher; Roberta Shanman; Marika S Booth; Jeremy N V Miles; Melony E Sorbero; Susanne Hempel
Journal:  Syst Rev       Date:  2016-09-02

Review 6.  Dry Needling and Antithrombotic Drugs.

Authors:  María Muñoz; Jan Dommerholt; Sara Pérez-Palomares; Pablo Herrero; Sandra Calvo
Journal:  Pain Res Manag       Date:  2022-01-07       Impact factor: 3.037

Review 7.  The critical interaction between valproate sodium and warfarin: case report and review.

Authors:  Chenguang Zhou; Yi Sui; Weijin Zhao; Chunyao Dong; Li Ren; Pingmei Song; Bing Xu; Xiaohong Sun
Journal:  BMC Pharmacol Toxicol       Date:  2018-10-01       Impact factor: 2.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.